These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 16330224

  • 1. Changes in biological source material.
    Robertson JS.
    Biologicals; 2006 Mar; 34(1):61-3. PubMed ID: 16330224
    [Abstract] [Full Text] [Related]

  • 2. Process changes and their effect on process evaluation for viral clearance.
    Marcus-Sekura C.
    Dev Biol Stand; 1996 Mar; 88():125-30. PubMed ID: 9119123
    [Abstract] [Full Text] [Related]

  • 3. Regulatory perspectives from Japan - comparability of biopharmaceuticals.
    Kawanishi T.
    Biologicals; 2006 Mar; 34(1):65-8. PubMed ID: 16330220
    [Abstract] [Full Text] [Related]

  • 4. Viral safety and clearance evaluation--implications for process change and comparability.
    Dinowitz M.
    Dev Biol (Basel); 2002 Mar; 109():121-6. PubMed ID: 12434921
    [Abstract] [Full Text] [Related]

  • 5. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M, Girardin E, Kapetanovic L, Ho K, Trouvin JH.
    Horm Res; 2008 Mar; 69(1):14-21. PubMed ID: 18059081
    [Abstract] [Full Text] [Related]

  • 6. Current and future approaches to ensure the viral safety of biopharmaceuticals.
    Brorson K, Norling L, Hamilton E, Lute S, Lee K, Curtis S, Xu Y.
    Dev Biol (Basel); 2004 Mar; 118():17-29. PubMed ID: 15645669
    [No Abstract] [Full Text] [Related]

  • 7. Characterizing biological products and assessing comparability following manufacturing changes.
    Chirino AJ, Mire-Sluis A.
    Nat Biotechnol; 2004 Nov; 22(11):1383-91. PubMed ID: 15529163
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. An industry perspective on plasma-derived products.
    von Hoegen I.
    Dev Biol (Basel); 2004 Nov; 118():31-5. PubMed ID: 15645670
    [No Abstract] [Full Text] [Related]

  • 10. Examination of the biological safety of a drug derived from mammalian organs.
    Hübner GE, Koch RC, Sprenger KB, Stadler PJ, Gölker CF.
    Arzneimittelforschung; 1996 Jun; 46(6):657-61. PubMed ID: 8767361
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Current issues in viral assays and viral clearance evaluation.
    Lubiniecki AS.
    Dev Biol Stand; 1996 Jun; 88():9-11. PubMed ID: 9119167
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies.
    Putnam WS, Prabhu S, Zheng Y, Subramanyam M, Wang YM.
    Trends Biotechnol; 2010 Oct; 28(10):509-16. PubMed ID: 20691488
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Minimum safety requirements for preclinical testing.
    Dorner F, Barrett PN, Schwartz HP, Eibl H.
    Dev Biol Stand; 1993 Oct; 81():245-52. PubMed ID: 8174809
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.